Menu
Submit Data
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Back to Studies

Mod GRF 1-29

Sermorelin, Growth Hormone Releasing Hormone (1-29), hGRF(1-29)NH2

Quick Stats
Studies 227
Trials 47
Overview Studies Clinical Trials
Score 3
1986 pubmed 34 citations

Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine.

Valcavi. R R; Jordan. V V; Dieguez. C C; John. R R; Manicardi. E E; Portioli. I I; Rodriguez-Arnao. M D MD; Gomez-Pan. A A; Hall. R R; Scanlon. M F MF

View on DOI View Original Source

Key Findings

  • Primary hypothyroidism blunts GH release after a GRF 1-29 injection.
  • Thyroxine (T4) replacement significantly raises both peak GH levels and overall GH exposure (AUC) after GRF 1-29.
  • The improvement was seen in the majority of participants (9‑10 out of 14).

Practical Outcomes

  • If you plan to use GRF 1-29 (e.g., sermorelin) for GH boosting, first check your thyroid function. Correcting hypothyroidism with T4 can make the peptide work better. In practice, ensure you are euthyroid before dosing GRF 1-29 for optimal GH response.

Summary

In people with an underactive thyroid, the body doesn't release as much growth hormone (GH) when given the peptide GRF 1-29. Giving thyroid hormone (T4) restores the thyroid and makes the GH response to GRF 1-29 much stronger.

Abstract

It is well known that hypothyroidism is frequently associated with impaired GH responses to different stimuli. In the present study we have evaluated GH responses to GH-releasing factor (GRF) in patients with primary hypothyroidism before and during T4 replacement therapy. Fourteen patients (age range 26-60 years) underwent two GRF tests (1 microgram/kg) before and during replacement therapy (150 micrograms/d). Administration of T4 increased peak GH responses to GRF in 9 patients and in the group as a whole (mean +/- SEM, 17.0 +/- 2.8 vs 32.6 +/- 5.7 mU/l, P less than 0.02). When the data are analysed by means of area under the curve (AUC), the GH response to GRF was increased by T4 in 10 patients and in the group as a whole (mean +/- SEM, 51.7 +/- 14.3 vs 101.5 +/- 28.1, P less than 0.02). These data indicate that thyroid hormone replacement therapy enhances the responsiveness of the somatotroph to GRF 1-29 in patients with primary hypothyroidism.

Study Information

Provider

pubmed

Year

1986

Date

1986-06-01T00:00:00.000Z

DOI

10.1111/j.1365-2265.1986.tb01666.x

Citations

34

References

26